Back to CITADEL ADVISORS LLC CITADEL ADVISORS LLC

MREOMREO
Showing 7 of 23 quarters

Position history for CITADEL ADVISORS LLCCITADEL ADVISORS LLC's holdings in MEREO BIOPHARMA GROUP PLC

CITADEL ADVISORS LLC holds 444,158 shares of MREO (MEREO BIOPHARMA GROUP PLC), worth $141,109 as of 2026-Q2. This is a new position.

Current Value

$141,109

Current Shares

444,158

Total Value Change

-$394,252

Total Shares Change

+313,900

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
New
444,158
-
$141,1090.0%$0.32
34
2025-Q4
Exited
0
-100.0%
$00.0%$0.37
0
2025-Q3
Increased
3.2M
+317.0%
$6.5M0.0%$1.96
44
2025-Q2
Increased
760,659
+121.3%
$2.1M0.0%$2.66
42
2025-Q1
Increased
343,653
+9.5%
$773,2190.0%$2.30
27
2024-Q4
Increased
313,950
+141.0%
$1.1M0.0%$3.52
41
2024-Q3
Decreased
130,258
-68.2%
$535,3610.0%$4.14
0

Other major holders of MREO: Janus Henderson Group Ltd., ADAGE CAPITAL PARTNERS GP, L.L.C.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used